VANCOMYCIN HYDROCHLORIDE - Generic Drug Details

What are the generic sources for vancomycin hydrochloride and what is the scope of patent protection?

Vancomycin hydrochloride is the generic ingredient in seven branded drugs marketed by Ani Pharms, Abon Pharms Llc, Fresenius Kabi Usa, Lupin Ltd, Orient Pharma Co Ltd, Strides Pharma, Watson Labs, Azurity, Lederle, Alkem Labs Ltd, Amneal, Steriscience, Hikma, Aspiro, Avet Lifesciences, Eugia Pharma, Gland, Hikma Pharms, Hospira, Hospira Inc, Knack, Medimetriks Pharms, Meitheal, Mylan Labs Ltd, Plano Pharms, Sagent Pharms, Slate Run Pharma, Teva Pharms Usa, Xellia Pharms Aps, Pharmacia And Upjohn, Samson Medcl, Zhejiang Novus Pharm, and Baxter Hlthcare, and is included in sixty-five NDAs. There are thirteen patents protecting this compound. Additional information is available in the individual branded drug profile pages.

Vancomycin hydrochloride has fifty-eight patent family members in twenty-nine countries.

There are twenty drug master file entries for vancomycin hydrochloride. Thirty-two suppliers are listed for this compound.

Summary for VANCOMYCIN HYDROCHLORIDE

International Patents:	58
US Patents:	13
Tradenames:	7
Applicants:	33
NDAs:	65
Drug Master File Entries:	20
Finished Product Suppliers / Packagers:	32
Raw Ingredient (Bulk) Api Vendors:	1
Clinical Trials:	473
Patent Applications:	1,768
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for VANCOMYCIN HYDROCHLORIDE
What excipients (inactive ingredients) are in VANCOMYCIN HYDROCHLORIDE?	VANCOMYCIN HYDROCHLORIDE excipients list
DailyMed Link:	VANCOMYCIN HYDROCHLORIDE at DailyMed

Recent Clinical Trials for VANCOMYCIN HYDROCHLORIDE

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Ganesh M. Shankar	PHASE2
Medical College of Wisconsin	EARLY_PHASE1
The Methodist Hospital Research Institute	PHASE2

See all VANCOMYCIN HYDROCHLORIDE clinical trials

Pharmacology for VANCOMYCIN HYDROCHLORIDE

Drug Class

Glycopeptide Antibacterial

Medical Subject Heading (MeSH) Categories for VANCOMYCIN HYDROCHLORIDE

Anti-Bacterial Agents

Anatomical Therapeutic Chemical (ATC) Classes for VANCOMYCIN HYDROCHLORIDE

A07AA	Antibiotics
A07A	INTESTINAL ANTIINFECTIVES
A07	ANTIDIARRHEALS, INTESTINAL ANTIINFLAMMATORY/ANTIINFECTIVE AGENTS
A	Alimentary tract and metabolism

J01XA	Glycopeptide antibacterials
J01X	OTHER ANTIBACTERIALS
J01	ANTIBACTERIALS FOR SYSTEMIC USE
J	Antiinfectives for systemic use

S01AA	Antibiotics
S01A	ANTIINFECTIVES
S01	OPHTHALMOLOGICALS
S	Sensory organs

Paragraph IV (Patent) Challenges for VANCOMYCIN HYDROCHLORIDE

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
FIRVANQ KIT	For Oral Solution	vancomycin hydrochloride	25 mg/mL and 50 mg/mL	208910	1	2020-05-18

US Patents and Regulatory Information for VANCOMYCIN HYDROCHLORIDE

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Plano Pharms	VANCOMYCIN HYDROCHLORIDE	vancomycin hydrochloride	INJECTABLE;INJECTION	090250-002	Apr 27, 2010		DISCN	No	No
Hikma	TYZAVAN	vancomycin hydrochloride	SOLUTION;INTRAVENOUS	211962-006	May 13, 2020		RX	Yes	Yes	11,628,200		Y
Mylan Labs Ltd	VANCOMYCIN HYDROCHLORIDE	vancomycin hydrochloride	POWDER;INTRAVENOUS	209481-004	Jul 10, 2018	AP	RX	Yes	Yes
Hikma	TYZAVAN	vancomycin hydrochloride	SOLUTION;INTRAVENOUS	211962-006	May 13, 2020		RX	Yes	Yes	10,188,697		Y
Teva Pharms Usa	VANCOMYCIN HYDROCHLORIDE	vancomycin hydrochloride	INJECTABLE;INJECTION	201250-002	Dec 23, 2015		DISCN	No	No
Mylan Labs Ltd	VANCOMYCIN HYDROCHLORIDE	vancomycin hydrochloride	POWDER;INTRAVENOUS	209481-001	Jul 10, 2018		DISCN	Yes	No

International Patents for VANCOMYCIN HYDROCHLORIDE

Country	Patent Number	Title	Estimated Expiration
Japan	2017508807
European Patent Office	3542812	COMPOSITIONS DE GLYCOPEPTIDE (GLYCOPEPTIDE COMPOSITIONS)
World Intellectual Property Organization (WIPO)	2015138983
Brazil	112017009405
Spain	2903419
China	107073072	糖肽组合物 (Glycopeptide compositions)

Market Dynamics and Financial Trajectory for Vancomycin Hydrochloride

Last updated: July 27, 2025

Introduction

Vancomycin Hydrochloride remains a cornerstone antibiotic in combating severe bacterial infections, particularly those caused by multi-drug resistant organisms such as MRSA (Methicillin-Resistant Staphylococcus aureus). Its strategic significance within hospitals and healthcare settings, combined with evolving microbial resistance, positions Vancomycin as a high-value product with notable market implications. This analysis explores the current market landscape, key drivers, competitive forces, regulatory environment, and financial outlook for Vancomycin Hydrochloride.

Market Overview

Global Market Size and Growth

The global antibiotics market, valued at approximately USD 53 billion in 2022, is projected to grow at a compound annual growth rate (CAGR) of around 3.5% through 2030, driven by escalating antimicrobial resistance and increasing infection rates. Vancomycin specifically constitutes a significant segment within this landscape, particularly in hospital-derived antibiotics. The increasing demand for effective treatments against resistant strains sustains demand for Vancomycin, despite the growth of newer alternatives and biosimilars.

Therapeutic Significance and Usage

Vancomycin Hydrochloride is predominantly administered intravenously for severe infections, including endocarditis, osteomyelitis, pneumonia, and septicemia. Its role as a first-line agent against resistant Gram-positive bacteria underscores its clinical importance. Oral formulations are limited but utilized for specific indications like C. difficile infections.

Supply Chain and Production

Manufacturing of Vancomycin involves complex fermentation processes, primarily sourced from microbial fermentation of Amycolatopsis orientalis. The production process is capital-intensive and governed by stringent quality standards, which serve as potential entry barriers for new entrants or biosimilar manufacturers.

Key Market Drivers

Rising Antibiotic Resistance

Antimicrobial resistance (AMR) poses an existential threat to healthcare, with the WHO identifying AMR as one of the top global health risks. The proliferation of MRSA, VRE (Vancomycin-Resistant Enterococci), and other resistant strains sustains the dependence on Vancomycin. According to CDC estimates, MRSA infections account for over 80,000 infections annually in the U.S., with significant mortality, amplifying Vancomycin’s critical role.

Regulatory Approvals and Expanding Indications

Regulatory agencies such as the FDA and EMA continuously evaluate Vancomycin's safety profile and approve new indications, broadening its market scope. Recent approvals for liposomal formulations and combination therapies could influence future sales trajectories.

Hospital and Critical Care Demand

Vancomycin's primary administration route in hospital settings ensures high-volume usage. Growth in ICU admissions and hospitalizations, especially amidst the COVID-19 pandemic, sustain demand.

Strategic Generic Production

Emerging patent expirations and increased generics production reduce manufacturing costs and price points, expanding access but exerting downward pressure on per-unit revenues.

Market Challenges

Biosimilar and Generic Competition

Patent expirations and the proliferation of biosimilars and generics have intensified price competition, reducing profit margins for innovator companies. The FDA approved numerous vancomycin generics, significantly impacting market share dynamics.

Adverse Effect Profile and Resistance Risks

Potential nephrotoxicity and ototoxicity, alongside emerging resistance, may limit usage in certain populations, constraining volume growth.

Alternative Therapies and Novel Agents

Emergence of newer antimicrobial agents such as linezolid, daptomycin, and newer cephalosporins pose substitution risks, especially when they demonstrate superior efficacy or safety profiles.

Regulatory Environment

Strict Good Manufacturing Practices (GMP) and antimicrobial stewardship programs influence supply and demand. Regulatory initiatives promoting rational antibiotic use aim to curb overprescription, potentially limiting volume growth for Vancomycin.

Furthermore, global health policies advocate for antibiotic stewardship, influencing prescribing patterns and market dynamics across regions.

Financial Trajectory and Market Outlook

Historical Financial Performance

Leading pharmaceutical companies manufacturing Vancomycin report steady revenues, with notable variances linked to generic market penetration. For instance, Teva Pharmaceuticals and Hikma Pharmaceuticals have significant market shares via generic Vancomycin formulations, collectively contributing to an estimated USD 600-800 million annually.

Forecasted Revenue Trends

Analysts project a modest CAGR of approximately 2-3% for Vancomycin revenues over the next decade, influenced by factors such as:

• Patent expirations of proprietary formulations from major players.
• Growing prevalence of resistant infections sustaining demand.
• Price reductions due to generic competition.
• Regional disparities, with higher growth expected in emerging markets due to increasing healthcare access.

Investment and R&D Implications

While R&D investment in Vancomycin itself is limited due to its established status, companies focus on formulation innovations, such as liposomal delivery systems (e.g., oritavancin), to differentiate offerings and extend product life cycles.

Pricing Dynamics

Per-unit prices have declined, with average wholesale prices (AWP) in North America decreasing by approximately 25% over five years, driven primarily by generic market entry. This scenario constrains profit margins but enhances accessibility.

Emerging Trends Impacting Future Market Dynamics

Development of Resistance Management Strategies

Prolonged Vancomycin use has led to resistance, prompting health authorities to establish guidelines for judicious use, influencing demand patterns.

Technological Innovations

Advances in rapid diagnostic testing enable targeted Vancomycin therapy, optimizing usage but potentially reducing unnecessary prescriptions.

Global Health Initiatives

Efforts such as the WHO Global Action Plan on Antimicrobial Resistance promote the development of new agents and stewardship programs, indirectly affecting the Vancomycin market.

Conclusion

Vancomycin Hydrochloride’s market outlook is characterized by a balancing act between clinical necessity driven by resistance and competitive challenges from generics and newer antibiotics. Its financial trajectory reflects mature market characteristics with modest growth prospects, though regional disparities and innovations could influence future dynamics.

Healthcare providers and pharmaceutical investors should monitor resistance trends, regulatory shifts, and technological developments to strategically position within the Vancomycin landscape.

---

Key Takeaways

• Vancomycin remains vital against resistant Gram-positive infections, ensuring sustained demand.
• Patent expirations and generic competition have exerted downward pressure on prices and profit margins.
• Growth is moderate, estimated at low single digits annually, with regional variances favoring emerging markets.
• Resistance development and stewardship programs may constrain usage volumes, impacting revenues.
• Innovation in formulations and diagnostic tools could provide differentiation avenues for manufacturers.

---

FAQs

Q1: How will rising antimicrobial resistance impact Vancomycin's market share?
A: Increased resistance may initially sustain demand but could also lead to the development and adoption of alternative therapies, potentially limiting long-term growth for Vancomycin.

Q2: Are biosimilars significantly affecting Vancomycin’s profitability?
A: Yes, biosimilar and generic entries have led to substantial price reductions, lowering profit margins but broadening access.

Q3: What regional trends are notable in Vancomycin’s market?
A: Developed regions like North America and Europe exhibit mature markets with price pressures, whereas emerging markets show growth potential due to increasing infection burdens and healthcare expansion.

Q4: What innovations are anticipated to influence Vancomycin's future market?
A4: Advanced delivery formulations, rapid diagnostics, and new combination therapies are expected to shape future demand and usage patterns.

Q5: How do regulatory policies affect Vancomycin sales?
A: Stricter antimicrobial stewardship policies promote judicious use, potentially reducing unnecessary prescriptions but ensuring continued demand for effective drugs like Vancomycin.

---

Sources:

1. MarketsandMarkets. "Antibiotics Market." 2022.
2. CDC. “Antibiotic Resistance Threats in the United States.” 2019.
3. Grand View Research. "Antimicrobial Drugs Market." 2022.
4. FDA. "Approved Drug Products: Vancomycin." 2023.
5. WHO. "Global Action Plan on Antimicrobial Resistance." 2015.